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component of the innate immune system specialized to kill host
cells that have become transformed or virally infected [1]. KIR are
diverse in terms of the number, type, and combination of genes
present in individuals, and display extensive polymorphism at the
nucleotide level. The ligands for NK receptors include the poly-
morphic human leukocyte antigen (HLA) class I cell surface mol-
ecules. Recent evidence suggests that interactions between an in-
dividual’s KIR molecular proﬁle and HLA class I ligands may play
an important role in stem cell transplant outcome; NK activation
may be of beneﬁt in hematopoietic transplants as donor NK cells
in a KIR/HLA mismatched transplant have shown the ability to
attack host leukemias and reduce graft versus host disease and graft
rejection [2,3,5]. Thus assessment of KIR genotypes may become
part of the donor selection process. As part of a larger study to
analyze the role of donor and recipient KIR and HLA ligand
proﬁles in stem cell transplantation, we are developing a novel,
high-throughput single nucleotide polymorphism (SNP)-based
KIR genotyping methodology. In this assay, the masses generated
in a SNP-based primer extension reaction are analyzed on a ma-
trix-assisted laser desorption/ionization time-of-ﬂight mass spec-
trometer (MALDI-TOF). The method uses 384-well microarray
chips, and is both highly accurate and rapid [4]. We present data
using this novel typing method to demonstrate that the method is
capable of accurately deﬁning KIR genotypes in a panel of 100
donor recipient pairs from the NMDP. We are collaborating with
the NMDP on an analysis of the KIR/HLA proﬁles of this panel
and their relationship to hematopoietic transplant outcomes.
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A study completed by the National Marrow Donor Program
(NMDP) evaluated search strategy proﬁciencies of U.S. transplant
centers in selecting matched unrelated donors (MUD). The three
objectives were: 1) to assess the quality of transplant center search
practices, 2) to evaluate effectiveness of NMDP services and 3) to
identify areas where further education is needed. Within the one
year study, the ﬁrst 5 new MUD searches were evaluated for each
transplant center. For centers with lower transplant activity, all
MUD searches were evaluated (15% had 4 searches). Search
indicators scored were: 1) patient HLA typing—loci and level of
resolution, 2) search strategy and 3) number of donors selected.
Scores were averaged and centers were placed into prospectively
determined groups. Center speciﬁc factors in the statistical evalu-
ation were: 1) use of NMDP HLA expert consultations, 2) receipt
of preliminary search reviews, 3) having Certiﬁed Hematopoietic
Transplant Coordinator (CHTC) staff, and 4) volume of unrelated
donor transplants per year. The study included 484 MUD searches
for 106 transplant centers. The cumulative scores separated
centers into three proﬁciency categories of high (56% of the
centers), medium (29%) and low (15%). Multivariate logistic
regression was performed to control for bias. Since the response
variable “proﬁciency category” is ordinal, a proportional odds
model was used, with the probability of having higher ranking
being modeled. After adjusting for other factors, expert HLA
consultations (P  .007) and CHTC (P  .03) signiﬁcantly
affected the proﬁciency ranking (Table 1). Centers with at least
one CHTC staff or centers using HLA expert consultations
tended to have higher rankings. Unrelated transplant volume
and receipt of NMDP preliminary search reviews did not sig-
niﬁcantly affect the performance ratings (Table 1). The majority
of the transplant centers scored in the highest category demon-
strating optimal practices. The transplant centers in the lowest
category tended to select too few donors and use less than
optimal resolution for recipient HLA typing, indicating a need
for targeted education in these areas. Two NMDP programs,
Certiﬁed Hematopoietic Transplant Coordinator and HLA
search consultation, were signiﬁcantly associated with optimal
search practices.
Table 1. Logistic Regression Result for TC Proﬁciency Rankings
Factor
Odds
Ratio
95%
CI
P
Value
Favorable
Characteristic
Center volume Not significant
Low 1  
Medium and high 1.85 (0.82, 4.15) .10
HLA consultant used? Used HLA consultant
No 1  
Yes 3.96 (1.45, 10.86) .007
CHTC staff Had CHTC staff
No 1  
Yes 2.46 (1.08, 5.57) .03
Preliminary reviews Not significant
No 1  
Yes 1.47 (0.67, 3.26) .30
80
TREATMENT FOR ACUTE MYELOGENOUS LEUKEMIA BY LOW DOSE
TOTAL BODY IRRADIATION (TBI) BASED CONDITIONING AND HEMA-
TOPOIETIC CELL TRANSPLANTATION FROM RELATED AND UNRE-
LATED DONORS
Franke, G.N.1, Hegenbart, U.1, Niederwieser, D.1,
Sandmaier, B.M.2,3, Maris, M.B.2,3, Shizuru, J.A.4, Stuart, M.4,
Greinix, H.5, Cordonnier, C.6, Rio, B.7, Gratwohl, A.8, Lange, T.1,
Poenisch, W.1, Grommisch, L.1, Al-Ali, H.1, Storer, B.2,3,
Maloney, D.2,3, Petersdorf, E.2,3, McSweeney, P.9, Chauncey, T.2,3,10,
Agura, E.11, Epner, E.12, Maziarz, R.T.13, Petersen, F.14, Bruno, B.15,
Storb, R.2,3 1University of Leipzig, Leipzig, Germany; 2Fred Hutchin-
son Cancer Research Center, Seattle, WA; 3University of Washington,
Seattle, WA; 4Stanford University, Palo Alto, CA; 5Bone Marrow
Transplant Unit, Medical University of Vienna, Vienna, Austria; 6Ho-
pital Henri Mondor, Creteil, France; 7Hotel Dieu, Paris, France; 8Uni-
versity Hospital, Bale, Switzerland; 9University of Colorado, Denver,
CO; 10Seattle Veterans Administration Medical Center, Seattle, WA;
11Baylor University, Dallas, TX; 12University of Arizona, Tucson, AR;
13Oregon Health & Science University, Portland, OR; 14University of
Utah, Salt Lake City, UT; 15University of Torino, Torino, Italy.
Conventional allogeneic hematopoietic cell transplantation
(HCT) is an effective treatment for patients with acute myeloge-
nous leukemia (AML), but its use is restricted to younger individ-
uals in good medical condition. The use of low-dose irradiation
based preparative regimens has allowed the extension of allograft-
ing to older and medically inﬁrm patients. The present study
included 122 patients, 117 of whom were ineligible for conven-
tional HCT. Their disease stages ranged from complete remission
(CR1) to resistant AML. Patients were conditioned with 200 cGy
TBI on day 0 with or without preceding ﬂudarabine (30 mg/m2/
day from days 4 to 2), and given postgrafting cyclosporine at
6.25 mg/kg twice daily from day 3 and mycophenolate mofetil at
15 mg/kg twice daily from day 0. Human leukocyte antigen (HLA)
matched related donors were used in 58 and HLA matched/par-
tially mismatched unrelated donors in 64 patients. Among the
121 evaluable patients, 117 (96.7%) had durable hematopoietic
engraftment. Cumulative incidences of acute graft-versus-host
disease (GvHD) grades II-IV at 6 months were 33% after
related and 42% after unrelated HCT, respectively. With a
median follow up of 17 months (range 4-57), 58 patients were
alive, 53 of whom were in complete remission. Cumulative
non-relapse mortalities were 12% and 27%, and cumulative
mortalities from disease progression were 46% and 34% at 2
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